Feb 23, 2021
Phio Pharmaceuticals to Participate in the H.C. Wainwright Global Life Sciences Conference on March 9th-10th
Feb 12, 2021
Phio Pharmaceuticals Announces $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market
Jan 21, 2021
Phio Pharmaceuticals Announces $14.0 Million Private Placement Priced At-the-Market
Nov 19, 2020
Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference
Nov 09, 2020
Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment
Oct 26, 2020
Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Sep 09, 2020
Phio Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Aug 12, 2020
Phio Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
Jun 22, 2020
Phio Presents Additional Data Supporting Potential of TIGIT Targeting INTASYL Compound in the Tumor Microenvironment at AACR 2020
Jun 08, 2020
Phio Pharmaceuticals to Host Key Opinion Leader Call on Intratumoral Therapy with Self-Delivering RNAi on Friday, June 12th
May 29, 2020
Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity
May 14, 2020
Phio Presents Data on INTASYL as an Alternative to Genetic Modification to Improve Cell-based Immunotherapy at ASGCT 2020
May 12, 2020
Phio Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
Apr 02, 2020
Phio Pharmaceuticals Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market
Mar 31, 2020
Phio Announces Positive New Data Validating the INTASYL(TM) Immunotherapy Platform's Ability to Develop Novel Compounds Capable of Inhibiting Cancer Tumor Growth
Mar 31, 2020
Phio Pharmaceuticals Announces $4.0 Million Registered Direct Offering Priced At-the-Market
Mar 26, 2020
Phio Pharmaceuticals Reports Year End 2019 Financial Results and Provides Business Update
Mar 10, 2020
Phio Pharmaceuticals and Helmholtz Zentrum München Announce Collaboration and Option Agreement with Medigene
Feb 13, 2020
Phio Pharmaceuticals Announces Closing of $8.0 Million Underwritten Public Offering
Feb 11, 2020
Phio Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering